Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Stereotactic radioactive particle brachytherapy plus sintilimab for refractory solid malignant tumors
ChiCTR2000039748Phase 2Recruiting
- Sponsor
- Affiliated Zhongshan Hospital of Dalian University
- Start
- Nov 2020
- Modality
- Monoclonal Antibodies → Antibody-Based Therapeutics
- Countries
- 1
01
Overview
Phase 2, open-label, single-arm trial of sintilimab in Non-hematologic malignancy, sponsored by Affiliated Zhongshan Hospital of Dalian University. Primary endpoints: Objective response rate, Progression-free survival and 2 more. Started Nov 2020; status: recruiting.
02
Drugs
sintilimab
03
Conditions
Non-hematologic malignancy
Beyond the preview
Go deeper on ChiCTR2000039748.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on ChiCTR2000039748.